A short course of darolutamide (Nubeqa) enhanced the imaging signal of prostate-specific membrane antigen (PSMA)-PET in a ...
Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...
A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...
The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...
Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer Patients with newly diagnosed LPCa with Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were ...
Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors We analyzed whole exomes of patient-matched pre- and ...
Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical results published Aug ...
Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment ...
Researchers have created an epigenetic tool which has implications for medicine, sports, and agriculture. Researchers from the University of Otago -- Ōtākou Whakaihu Waka have created a world-first ...
Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer. Alicia Morgans, M.D., MPH: Androgen deprivation therapy, sometimes called ADT or hormonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results